Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1401786 | 1.00 | PKM (0.38) | PKMCHRM5CHRM3CHRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL8438777 | 0.93 | CXCR4 (0.47) | PKMCHRM5CHRM3CHRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL6476259 | 0.88 | CXCR4 (0.43) | PKMCHRM5CHRM3CHRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL3470280 | 0.87 | ALOX15 (0.41) | PKMCHRM5CHRM3CHRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL6477387 | 0.84 | MEN1 (0.45) | PKMCHRM5CHRM3CHRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL22123107 | 0.84 | KDM4E (0.39) | PKMCHRM5CHRM3CHRM2CHRM4 | |
| SCHEMBL211275 | 0.82 | — | — | |
| Trifluoroacetic Acid SCHEMBL29384411 | 0.81 | CXCR4 (0.43) | PKMCHRM5CHRM3CHRM2CHRM4 | |
| Trifluoroacetic Acid SCHEMBL21816718 | 0.80 | MEN1 (0.46) | PKMCHRM5CHRM3KDM4EHSD17B10 | |
| Trifluoroacetic Acid SCHEMBL2356674 | 0.80 | MEN1 (0.52) | PKMSMN1; SMN2KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-7994176-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| EP-2292615-A1 | Quinazoline compounds | AstraZeneca AB (SE) | 2011-03-09 | — | — | EP | disclosed |
| US-7816349-B2 | Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2029529-B1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-07-07 | — | — | EP | disclosed |
| EP-2021337-B1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090156821-A1 | Quinazoline compounds | ASTRAZENECA AB | 2009-06-18 | — | — | US | disclosed |
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-16 | — | — | US | disclosed |
| US-20090069326-A1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| EP-2029529-A1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-2021337-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| WO-2007127693-A1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127726-A2 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-08 | — | — | WO | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | ASTRAZENECA AB (SE) | 2005-04-21 | — | — | US | disclosed |
| EP-1474420-A1 | QUINAZOLINE COMPOUNDS | Astrazeneca AB (SE) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003064413-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085465-A1 | Angiogenesis inhibitor; antiarthritic agents; psoriasis; anticancer agents | VEGFA, FLT4, FLT1 | PKM 4529/4885CHRM5 2676/4885CHRM3 4697/4885 |
| US-20090069326-A1 | SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | PKM 569/4885CHRM5 3997/4885CHRM3 4165/4885 |
| US-20090156821-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | PKM 4493/4885CHRM5 475/4885CHRM3 2273/4885 |
| US-20080027069-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | PKM 4493/4885CHRM5 475/4885CHRM3 2273/4885 |
| US-20090099182-A1 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD11B2, HSD3B1 | PKM 1657/4885CHRM5 4260/4885CHRM3 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.